Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

65.09 -0.78 (-1.18%)
Streaming Delayed Price Updated: 10:59 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corp

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness
Goldman Sachs downgraded Incyte Corp (NASDAQ: INCY), citing continued uncertainty around Jakafi (Ruxolitinib) lifecycle management ahead of the mid-27/late-28 EU/US  
Via Benzinga
The Latest Analyst Ratings for Incyte
Via Benzinga
Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents.
Investors should take notice ofINCYTE CORP (NASDAQ:INCY)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024
Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year. 
Via InvestorPlace
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
Exposures Economy
Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
Looking for growth without the hefty price tag? Consider INCYTE CORP (NASDAQ:INCY). 
Via Chartmill
Earnings Outlook For Incyte
Via Benzinga
Expert Ratings for Incyte
Via Benzinga
Analyst Ratings for Incyte
Via Benzinga
Goldman Sachs Maintains Buy Rating for Incyte: Here's What You Need To Know
Via Benzinga
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
INCYTE CORP (NASDAQ:INCY) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
Via InvestorPlace
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and... 
Via Benzinga
Exposures Product Safety
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer. 
Via Investor's Business Daily
Incyte's Earnings Outlook
Via Benzinga
Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales
Incyte's biggest moneymaker, Jakafi, missed first-quarter forecasts. 
Via Investor's Business Daily
Why Incyte Shares Are Falling Today
Incyte Corporation's (NASDAQ: INCY) shares are plunging today after the  
Via Benzinga
Earnings Outlook For Incyte
Via Benzinga
Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share
Incyte Corporation's (NASDAQ: INCY) Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago. 
Via Benzinga
Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023
Via Benzinga
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host... 
Via Benzinga
'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Alexandria Real Estate Equities, Inc. (NYSE: ARE) is "one of the better real estate investment trusts, but I would rather see you in Federal... 
Via Benzinga
Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children
Incyte Corporation (NASDAQ: INCY) released topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children with  
Via Benzinga
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape
Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a  
Via Benzinga
2 Low-Priced Stocks That Could Make You Richer
These two low-priced healthcare stocks could skyrocket within the next 12 months. 
Via The Motley Fool
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
The major indexes retreated for most of the week on banking fears, 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks
Incyte Corporation (NASDAQ: INCY) will report Q1 FY23 results on May 2.  Investor focus remains on the Opzelura launch, which has faced some hiccups over the first 18 months of launch and began to gain... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.